L'intraconazolo nella dermatite atopica dell'adulto

Translated title of the contribution: Itraconazole in adult atopic dermatitis

R. Caputo, M. Barbareschi, S. Veraldi

Research output: Contribution to journalArticle

Abstract

Aim. Clinical evidences showed that the clinical course of atopic dermatitis (AD) is often complicated by bacterial super-infections. In cutaneous areas, as face and neck, atopic dermatitis could be exacerbated by colonization of Pityrosporum species. In this study, the therapeutical activity of systemic Itraconazole has been evaluated in face and neck atopic dermatitis in which Pityrosporum species colonization has been demonstrated. Methods. A total of 8 adult patients were enrolled in the study. All patients had a high-grade face and neck atopic dermatitis and a reported resistance to all previous scheduled treatments. Itraconazole was given at the dose of 200 mg/day for 7 consecutive days. The evaluation of clinical effects has been scheduled before the treatment and after 2 and 4 weeks. Results. At the end of the treatment, clinical results have been classified as good in 50% of cases, excellent in 37.5% and negative in 12.5% of cases. Microscopic observation of cutaneous scales taken from affected areas gave positive results in 7 out of 8 enrolled patients. Conclusion. The study pointed out the therapeutical effect of Itraconazole in high-grade face and neck atopic dermatitis in which Malassezia colonization has been proven. Itraconazole has a specific effect on yeasts proliferation and it improves the clinical spectrum through its anti-inflammatory properties. It seems mandatory, to check for the presence of bacteria, and/or mycotic super-infections, in all the cases of high grade face and neck atopic dermatitis showing therapeutic resistance to common systemic and/or topical preparations.

Original languageItalian
Pages (from-to)345-350
Number of pages6
JournalGiornale Italiano di Dermatologia e Venereologia
Volume139
Issue number4
Publication statusPublished - 2004

Fingerprint

Itraconazole
Atopic Dermatitis
Malassezia
Neck
Skin
Therapeutics
Bacterial Infections
Anti-Inflammatory Agents
Yeasts
Bacteria
Infection

ASJC Scopus subject areas

  • Dermatology

Cite this

L'intraconazolo nella dermatite atopica dell'adulto. / Caputo, R.; Barbareschi, M.; Veraldi, S.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 139, No. 4, 2004, p. 345-350.

Research output: Contribution to journalArticle

@article{3ccdf7868b67442bbe09970ab5938ac8,
title = "L'intraconazolo nella dermatite atopica dell'adulto",
abstract = "Aim. Clinical evidences showed that the clinical course of atopic dermatitis (AD) is often complicated by bacterial super-infections. In cutaneous areas, as face and neck, atopic dermatitis could be exacerbated by colonization of Pityrosporum species. In this study, the therapeutical activity of systemic Itraconazole has been evaluated in face and neck atopic dermatitis in which Pityrosporum species colonization has been demonstrated. Methods. A total of 8 adult patients were enrolled in the study. All patients had a high-grade face and neck atopic dermatitis and a reported resistance to all previous scheduled treatments. Itraconazole was given at the dose of 200 mg/day for 7 consecutive days. The evaluation of clinical effects has been scheduled before the treatment and after 2 and 4 weeks. Results. At the end of the treatment, clinical results have been classified as good in 50{\%} of cases, excellent in 37.5{\%} and negative in 12.5{\%} of cases. Microscopic observation of cutaneous scales taken from affected areas gave positive results in 7 out of 8 enrolled patients. Conclusion. The study pointed out the therapeutical effect of Itraconazole in high-grade face and neck atopic dermatitis in which Malassezia colonization has been proven. Itraconazole has a specific effect on yeasts proliferation and it improves the clinical spectrum through its anti-inflammatory properties. It seems mandatory, to check for the presence of bacteria, and/or mycotic super-infections, in all the cases of high grade face and neck atopic dermatitis showing therapeutic resistance to common systemic and/or topical preparations.",
keywords = "Atopic dermatitis, Itraconazole, Pityrosporum",
author = "R. Caputo and M. Barbareschi and S. Veraldi",
year = "2004",
language = "Italian",
volume = "139",
pages = "345--350",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - L'intraconazolo nella dermatite atopica dell'adulto

AU - Caputo, R.

AU - Barbareschi, M.

AU - Veraldi, S.

PY - 2004

Y1 - 2004

N2 - Aim. Clinical evidences showed that the clinical course of atopic dermatitis (AD) is often complicated by bacterial super-infections. In cutaneous areas, as face and neck, atopic dermatitis could be exacerbated by colonization of Pityrosporum species. In this study, the therapeutical activity of systemic Itraconazole has been evaluated in face and neck atopic dermatitis in which Pityrosporum species colonization has been demonstrated. Methods. A total of 8 adult patients were enrolled in the study. All patients had a high-grade face and neck atopic dermatitis and a reported resistance to all previous scheduled treatments. Itraconazole was given at the dose of 200 mg/day for 7 consecutive days. The evaluation of clinical effects has been scheduled before the treatment and after 2 and 4 weeks. Results. At the end of the treatment, clinical results have been classified as good in 50% of cases, excellent in 37.5% and negative in 12.5% of cases. Microscopic observation of cutaneous scales taken from affected areas gave positive results in 7 out of 8 enrolled patients. Conclusion. The study pointed out the therapeutical effect of Itraconazole in high-grade face and neck atopic dermatitis in which Malassezia colonization has been proven. Itraconazole has a specific effect on yeasts proliferation and it improves the clinical spectrum through its anti-inflammatory properties. It seems mandatory, to check for the presence of bacteria, and/or mycotic super-infections, in all the cases of high grade face and neck atopic dermatitis showing therapeutic resistance to common systemic and/or topical preparations.

AB - Aim. Clinical evidences showed that the clinical course of atopic dermatitis (AD) is often complicated by bacterial super-infections. In cutaneous areas, as face and neck, atopic dermatitis could be exacerbated by colonization of Pityrosporum species. In this study, the therapeutical activity of systemic Itraconazole has been evaluated in face and neck atopic dermatitis in which Pityrosporum species colonization has been demonstrated. Methods. A total of 8 adult patients were enrolled in the study. All patients had a high-grade face and neck atopic dermatitis and a reported resistance to all previous scheduled treatments. Itraconazole was given at the dose of 200 mg/day for 7 consecutive days. The evaluation of clinical effects has been scheduled before the treatment and after 2 and 4 weeks. Results. At the end of the treatment, clinical results have been classified as good in 50% of cases, excellent in 37.5% and negative in 12.5% of cases. Microscopic observation of cutaneous scales taken from affected areas gave positive results in 7 out of 8 enrolled patients. Conclusion. The study pointed out the therapeutical effect of Itraconazole in high-grade face and neck atopic dermatitis in which Malassezia colonization has been proven. Itraconazole has a specific effect on yeasts proliferation and it improves the clinical spectrum through its anti-inflammatory properties. It seems mandatory, to check for the presence of bacteria, and/or mycotic super-infections, in all the cases of high grade face and neck atopic dermatitis showing therapeutic resistance to common systemic and/or topical preparations.

KW - Atopic dermatitis

KW - Itraconazole

KW - Pityrosporum

UR - http://www.scopus.com/inward/record.url?scp=7644240704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7644240704&partnerID=8YFLogxK

M3 - Articolo

VL - 139

SP - 345

EP - 350

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 4

ER -